bluebird bio Inc (NASDAQ:BLUE) insider David Davidson sold 3,101 shares of the business’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $146.41, for a total value of $454,017.41. Following the completion of the sale, the insider now owns 34,717 shares in the company, valued at $5,082,915.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

David Davidson also recently made the following trade(s):

  • On Monday, March 4th, David Davidson sold 4,910 shares of bluebird bio stock. The shares were sold at an average price of $155.77, for a total value of $764,830.70.
  • On Monday, February 4th, David Davidson sold 4,910 shares of bluebird bio stock. The shares were sold at an average price of $134.30, for a total value of $659,413.00.
  • On Friday, January 18th, David Davidson sold 2,035 shares of bluebird bio stock. The shares were sold at an average price of $130.05, for a total value of $264,651.75.
  • On Thursday, January 3rd, David Davidson sold 7,600 shares of bluebird bio stock. The shares were sold at an average price of $98.82, for a total value of $751,032.00.

BLUE opened at $158.04 on Friday. bluebird bio Inc has a 52-week low of $87.49 and a 52-week high of $211.80. The stock has a market cap of $8.68 billion, a P/E ratio of -14.80 and a beta of 2.64.

bluebird bio (NASDAQ:BLUE) last released its earnings results on Thursday, February 21st. The biotechnology company reported ($2.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.83) by $0.11. bluebird bio had a negative return on equity of 32.15% and a negative net margin of 1,018.02%. The business had revenue of $19.20 million for the quarter, compared to analyst estimates of $9.06 million. During the same quarter in the prior year, the company posted ($2.52) earnings per share. bluebird bio’s revenue was up 357.1% on a year-over-year basis. On average, analysts expect that bluebird bio Inc will post -11.67 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in BLUE. Cornerstone Advisors Inc. increased its position in bluebird bio by 1,540.0% during the fourth quarter. Cornerstone Advisors Inc. now owns 328 shares of the biotechnology company’s stock worth $33,000 after buying an additional 308 shares during the last quarter. Exane Derivatives acquired a new position in shares of bluebird bio in the fourth quarter valued at approximately $34,000. Stratos Wealth Partners LTD. acquired a new position in shares of bluebird bio in the third quarter valued at approximately $106,000. Belpointe Asset Management LLC acquired a new position in shares of bluebird bio in the third quarter valued at approximately $110,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in shares of bluebird bio by 36.6% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,104 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 296 shares during the last quarter.

A number of analysts have recently commented on BLUE shares. JPMorgan Chase & Co. restated a “buy” rating on shares of bluebird bio in a report on Thursday, January 10th. ValuEngine lowered bluebird bio from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 2nd. Oppenheimer restated a “hold” rating on shares of bluebird bio in a report on Friday, January 11th. Zacks Investment Research lowered bluebird bio from a “hold” rating to a “sell” rating in a report on Monday, February 11th. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $134.00 price target on shares of bluebird bio in a report on Monday, December 3rd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. bluebird bio presently has an average rating of “Buy” and an average target price of $168.12.

COPYRIGHT VIOLATION WARNING: “David Davidson Sells 3,101 Shares of bluebird bio Inc (BLUE) Stock” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/david-davidson-sells-3101-shares-of-bluebird-bio-inc-blue-stock/2897070.html.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

Featured Article: Special Dividends

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.